PL405076A1 - Zastosowanie alpha-cyklodrkstryny do wytwarzania leku do obnizenia poziomów leptyny, poziomów insuliny lub opornosci na insuline - Google Patents
Zastosowanie alpha-cyklodrkstryny do wytwarzania leku do obnizenia poziomów leptyny, poziomów insuliny lub opornosci na insulineInfo
- Publication number
- PL405076A1 PL405076A1 PL405076A PL40507603A PL405076A1 PL 405076 A1 PL405076 A1 PL 405076A1 PL 405076 A PL405076 A PL 405076A PL 40507603 A PL40507603 A PL 40507603A PL 405076 A1 PL405076 A1 PL 405076A1
- Authority
- PL
- Poland
- Prior art keywords
- levels
- insulin
- cyclodextrin
- medicament
- manufacture
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 6
- 102000004877 Insulin Human genes 0.000 title abstract 3
- 108090001061 Insulin Proteins 0.000 title abstract 3
- 206010022489 Insulin Resistance Diseases 0.000 title abstract 3
- 102000016267 Leptin Human genes 0.000 title abstract 3
- 108010092277 Leptin Proteins 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 229940125396 insulin Drugs 0.000 title abstract 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 title abstract 3
- 229940039781 leptin Drugs 0.000 title abstract 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 title 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 title 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 title 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 2
- 239000001116 FEMA 4028 Substances 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
- 229960004853 betadex Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D13/00—Finished or partly finished bakery products
- A21D13/80—Pastry not otherwise provided for elsewhere, e.g. cakes, biscuits or cookies
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/14—Organic oxygen compounds
- A21D2/18—Carbohydrates
- A21D2/181—Sugars or sugar alcohols
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/14—Organic oxygen compounds
- A21D2/18—Carbohydrates
- A21D2/186—Starches; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L15/00—Egg products; Preparation or treatment thereof
- A23L15/30—Addition of substances other than those covered by A23L15/20 – A23L15/25
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
- A23L25/10—Peanut butter
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/88—Taste or flavour enhancing agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/35—Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
- A23L5/27—Removal of unwanted matter, e.g. deodorisation or detoxification by chemical treatment, by adsorption or by absorption
- A23L5/273—Removal of unwanted matter, e.g. deodorisation or detoxification by chemical treatment, by adsorption or by absorption using adsorption or absorption agents, resins, synthetic polymers, or ion exchangers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/109—Types of pasta, e.g. macaroni or noodles
- A23L7/111—Semi-moist pasta, i.e. containing about 20% of moist; Moist packaged or frozen pasta; Pasta fried or pre-fried in a non-aqueous frying medium, e.g. oil; Packaged pasta to be cooked directly in the package
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
- A23L7/126—Snacks or the like obtained by binding, shaping or compacting together cereal grains or cereal pieces, e.g. cereal bars
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L9/00—Puddings; Cream substitutes; Preparation or treatment thereof
- A23L9/10—Puddings; Dry powder puddings
- A23L9/12—Ready-to-eat liquid or semi-liquid desserts, e.g. puddings, not to be mixed with liquids, e.g. water, milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P30/00—Shaping or working of foodstuffs characterised by the process or apparatus
- A23P30/40—Foaming or whipping
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Mycology (AREA)
- Child & Adolescent Psychology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
- Edible Oils And Fats (AREA)
- Fodder In General (AREA)
- Jellies, Jams, And Syrups (AREA)
- Confectionery (AREA)
Abstract
Wynalazek dotyczy zastosowania ?-cyklodekstryny do wytwarzania leku do obnizania poziomów leptyny, poziomów insuliny lub opornosci na insuline, w którym wymagajacemu tego podmiotowi podaje sie wystarczajaca ilosc leku do obnizenia poziomów leptyny, poziomów insuliny lub opornosci na insuline, przy czym stosunek ilosci podawanej ?-cyklodekstryny i ilosci tluszczu spozywanego dziennie przez wymieniony podmiot wynosi od 1:20 do 1:3 wagowo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40436602P | 2002-08-19 | 2002-08-19 | |
US46184703P | 2003-04-11 | 2003-04-11 | |
US48644003P | 2003-07-14 | 2003-07-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
PL405076A1 true PL405076A1 (pl) | 2013-12-09 |
PL220779B1 PL220779B1 (pl) | 2016-01-29 |
Family
ID=31892100
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL405077A PL220776B1 (pl) | 2002-08-19 | 2003-07-29 | Zastosowanie α-cyklodekstryny do wytwarzania leku do zmniejszania biegunki |
PL405075A PL220780B1 (pl) | 2002-08-19 | 2003-07-29 | Zastosowanie α-cyklodekstryny do wytwarzania leku do podwyższania poziomu cholesterolu lipoproteinowego o wysokiej gęstości (HDL) oraz do zmniejszania stosunku cholesterol/HDL |
PL396944A PL220645B1 (pl) | 2002-08-19 | 2003-07-29 | Zastosowanie α-cyklodekstryny do wytwarzania leku do ułatwiania utraty masy ciała |
PL405074A PL220643B1 (pl) | 2002-08-19 | 2003-07-29 | Zastosowanie α-cyklodekstryny do wytwarzania leku do obniżania poziomów trójglicerydów |
PL375374A PL213863B1 (pl) | 2002-08-19 | 2003-07-29 | Konsumpcyjny maczny produkt zywnosciowy, konsumpcyjny niemaczny produkt zywnosciowy, sposób polepszania organoleptycznych wlasciwosci zawierajacego tluszcz konsumpcyjnego produktu zywnosciowego i sposób zmniejszania dostepnosci biologicznej tluszczu w konsumpcyjnym zawierajacym tluszcz produkcie zywnosciowym |
PL405076A PL220779B1 (pl) | 2002-08-19 | 2003-07-29 | Zastosowanie α-cyklodekstryny do wytwarzania leku do obniżania poziomów leptyny, poziomów insuliny lub oporności na insulinę |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL405077A PL220776B1 (pl) | 2002-08-19 | 2003-07-29 | Zastosowanie α-cyklodekstryny do wytwarzania leku do zmniejszania biegunki |
PL405075A PL220780B1 (pl) | 2002-08-19 | 2003-07-29 | Zastosowanie α-cyklodekstryny do wytwarzania leku do podwyższania poziomu cholesterolu lipoproteinowego o wysokiej gęstości (HDL) oraz do zmniejszania stosunku cholesterol/HDL |
PL396944A PL220645B1 (pl) | 2002-08-19 | 2003-07-29 | Zastosowanie α-cyklodekstryny do wytwarzania leku do ułatwiania utraty masy ciała |
PL405074A PL220643B1 (pl) | 2002-08-19 | 2003-07-29 | Zastosowanie α-cyklodekstryny do wytwarzania leku do obniżania poziomów trójglicerydów |
PL375374A PL213863B1 (pl) | 2002-08-19 | 2003-07-29 | Konsumpcyjny maczny produkt zywnosciowy, konsumpcyjny niemaczny produkt zywnosciowy, sposób polepszania organoleptycznych wlasciwosci zawierajacego tluszcz konsumpcyjnego produktu zywnosciowego i sposób zmniejszania dostepnosci biologicznej tluszczu w konsumpcyjnym zawierajacym tluszcz produkcie zywnosciowym |
Country Status (23)
Country | Link |
---|---|
US (4) | US6890549B2 (pl) |
EP (4) | EP2623120B1 (pl) |
JP (3) | JP4418751B2 (pl) |
CN (1) | CN100542609C (pl) |
AT (1) | ATE442165T1 (pl) |
AU (1) | AU2003259235B2 (pl) |
BR (1) | BRPI0309572B1 (pl) |
CA (2) | CA2677430C (pl) |
CY (1) | CY1115026T1 (pl) |
DE (1) | DE60329168D1 (pl) |
DK (2) | DK2138190T3 (pl) |
ES (1) | ES2457017T3 (pl) |
HK (2) | HK1072184A1 (pl) |
IL (2) | IL164332A0 (pl) |
MA (1) | MA27959A1 (pl) |
MX (1) | MXPA04012880A (pl) |
NO (2) | NO334081B1 (pl) |
NZ (1) | NZ535665A (pl) |
PL (6) | PL220776B1 (pl) |
PT (1) | PT2138190E (pl) |
SI (1) | SI2138190T1 (pl) |
WO (1) | WO2004016101A2 (pl) |
ZA (1) | ZA200407806B (pl) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL164332A0 (en) * | 2002-08-19 | 2005-12-18 | Art Jen Complexus Inc | Compositions comprising dietary fat complexer and methods for their use |
US20040116382A1 (en) * | 2002-12-13 | 2004-06-17 | Plank David W. | Food products containing cyclodextrins having beneficial hypocholesterolemic effects and method of making and communicating the benefit of such products |
EP1447013A1 (en) * | 2003-02-14 | 2004-08-18 | Wacker-Chemie GmbH | Method for reducing the glycemic index of food |
US7105195B2 (en) * | 2003-07-25 | 2006-09-12 | General Mills, Inc. | Reduced trans fat product |
US7335386B2 (en) | 2003-07-30 | 2008-02-26 | Gerneral Mills, Inc. | Method for preventing acrylamide formation in food products and food intermediates |
US20040180125A1 (en) * | 2003-03-11 | 2004-09-16 | Plank David W. | Cyclodextrin-containing compositions and methods |
CA2547934C (en) | 2004-02-19 | 2013-05-21 | Abbott Laboratories | Methods of using gamma cyclodextrin to control blood glucose and insulin secretion |
US7780873B2 (en) * | 2004-02-23 | 2010-08-24 | Texas A&M University System | Bioactive complexes compositions and methods of use thereof |
DE602005004923T2 (de) * | 2004-06-22 | 2009-02-12 | General Mills, Inc., Minneapolis | Viskose fettzusammensetzungen mit niedrigem trans-fettgehalt, sowie verfahren und produkte |
US20070003681A1 (en) * | 2005-06-30 | 2007-01-04 | Kraft Foods Holdings, Inc. | Stable aerated food products containing oil and cyclodextrin |
AU2006335082B2 (en) * | 2005-12-22 | 2011-09-29 | General Mills, Inc. | Method of making complexed fat compositions |
WO2007073543A2 (en) * | 2005-12-22 | 2007-06-28 | General Mills, Inc. | Method of preferentially reducing absorption of saturated fat and compositions |
JP2008031055A (ja) * | 2006-06-29 | 2008-02-14 | Shunkosha:Kk | 酢酸を含有してなる摂取用組成物 |
US20090023682A1 (en) * | 2007-07-19 | 2009-01-22 | Joseph Artiss | Composition Comprising Dietary Fat Complexer and Methods of Using Same |
US20100112122A1 (en) * | 2008-04-30 | 2010-05-06 | Yun-Jeong Hong | Method of preferentially reducing absorbability of saturated fatty acids |
NZ589883A (en) | 2008-05-13 | 2012-06-29 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline |
WO2011114239A2 (en) * | 2010-03-13 | 2011-09-22 | Eastpond Laboratories Limited | Fat-binding compositions |
ES2679276T3 (es) * | 2010-05-14 | 2018-08-23 | Omega Pharma Innovation & Development Nv | Composición para reducir la absorción de grasa alimenticia |
CA3012773C (en) | 2010-10-19 | 2022-05-03 | L&F Research Llc | Assays, methods and kits for predicting renal disease and personalized treatment strategies |
US20120171184A1 (en) | 2010-12-31 | 2012-07-05 | Lajos Szente | Cellular hydration compositions |
WO2012090018A1 (en) | 2010-12-31 | 2012-07-05 | Eastpond Laboratories Limited | Cellular hydration compositions containing cyclodextrins |
EP4299121A2 (en) | 2012-04-13 | 2024-01-03 | L&F Research LLC | Method of using cyclodextrin |
US9636048B2 (en) | 2013-03-14 | 2017-05-02 | Group Mee Llc | Specialized sensors and techniques for monitoring personal activity |
JP6735964B2 (ja) * | 2016-04-28 | 2020-08-05 | 株式会社ハートテック | 血糖値上昇抑制の加工食品 |
KR20200107927A (ko) | 2017-09-28 | 2020-09-16 | 아스데라 엘엘씨 | 인지질 조절장애를 수반하는 질환 및 장애에서의 시클로덱스트린의 용도 |
JP7120068B2 (ja) * | 2018-02-28 | 2022-08-17 | トヨタ紡織株式会社 | 動物の育成方法及び育成装置 |
US11660283B2 (en) | 2018-12-19 | 2023-05-30 | Joyn Botanicals Ltd. | Cannabinoid-containing composition |
EP4132294A1 (en) | 2020-04-06 | 2023-02-15 | Eastpond Laboratories Limited | Compositions for promoting cellular hydration |
CN115104733A (zh) * | 2021-03-18 | 2022-09-27 | 南京壹盛康品生物科技有限公司 | α-环糊精在制备降脂食品、保健品及药物中的应用 |
CN115067393B (zh) * | 2022-05-31 | 2024-04-12 | 古茗科技集团有限公司 | 打发辅助剂、其的制备方法、应用及奶盖打发方法 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5210448A (en) | 1975-07-15 | 1977-01-26 | Teijin Ltd | Method of producing processed oil and fat food |
JPS6049752A (ja) | 1983-08-29 | 1985-03-19 | Sanyuu Shoji Kk | 栄養食品組成物 |
JPS6094912A (ja) * | 1983-10-28 | 1985-05-28 | Masashige Suzuki | 体内中性脂肪低減剤 |
JPS60149752A (ja) | 1984-01-11 | 1985-08-07 | Furukawa Electric Co Ltd:The | 高力アルミニウム合金導体の製造方法 |
JPS60219720A (ja) | 1984-04-16 | 1985-11-02 | 株式会社村田製作所 | 電気二重層コンデンサとその製造方法 |
JPS6211072A (ja) * | 1985-07-08 | 1987-01-20 | Kokusai:Kk | 痩身用食品 |
FR2601959B1 (fr) * | 1986-07-24 | 1988-12-02 | Monserbio Gie | Procede d'elimination du cholesterol contenu dans une matiere grasse d'origine animale et matiere grasse appauvrie en cholesterol obtenue |
US5232725A (en) | 1989-03-14 | 1993-08-03 | S.A.N. Corman | Process for reducing the content of cholesterol and of free fatty acids in an animal fat |
JPH0722483B2 (ja) | 1989-03-31 | 1995-03-15 | 鐘淵化学工業株式会社 | ケーキ用水中油型油脂組成物及びそれを利用したケーキ類の製造法 |
US5264241A (en) * | 1989-06-29 | 1993-11-23 | Roquette Freres | Process for manufacturing dairy products with a reduced sterol content |
US5264226A (en) * | 1989-07-12 | 1993-11-23 | Roquette Freres | Process for preparing dairy products with a low content of sterols, particularly of cholesterol |
JPH07115934B2 (ja) | 1989-10-12 | 1995-12-13 | 日本特殊陶業株式会社 | β―サイアロン焼結体 |
US5198250A (en) * | 1990-07-16 | 1993-03-30 | Lipotech Partners Limited Partnership | Food and pharmaceutical compositions containing short chain monounsaturated fatty acids and methods of using |
IT1243192B (it) | 1990-08-09 | 1994-05-24 | Staroil Ltd | Complessi di acidi grassi polinsaturi a lunga catena e di loro derivati, con ciclodestrine |
ES2033193B1 (es) * | 1990-10-30 | 1994-01-16 | Ganadera Union Ind Agro | Mezcla grasa para nutricion infantil y de adultos. |
JPH04237477A (ja) * | 1991-01-22 | 1992-08-25 | Ezaki Glico Co Ltd | メレンゲの製造法 |
JPH04333575A (ja) | 1991-01-29 | 1992-11-20 | Nippon Parkerizing Co Ltd | チタン含有金属材料上に複合被覆膜層を形成する方法 |
JP2646160B2 (ja) * | 1991-03-08 | 1997-08-25 | 美穂 田中 | 愛玩鳥類用飼料とその製造法 |
JPH06511270A (ja) * | 1991-09-06 | 1994-12-15 | コモンウェルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼイション | コレステロール濃度を低下させる組成物および方法 |
JPH05113603A (ja) | 1991-10-23 | 1993-05-07 | Tohoku Ricoh Co Ltd | オーバーヘツドプロジエクタ装置 |
US5254541A (en) * | 1991-11-15 | 1993-10-19 | Merck Frosst Canada, Inc. | (Quinolin-2-ylmethoxy)indole/cyclodextrin complex |
JP2559311B2 (ja) | 1991-12-12 | 1996-12-04 | 本田技研工業株式会社 | 多連スロットルボディの燃料配管構造 |
US5215922A (en) * | 1992-02-05 | 1993-06-01 | The Board Of Governors Of Wayne State University | Method and compositions for the determination of serum calcium using aersenazo III |
JPH05298849A (ja) | 1992-04-16 | 1993-11-12 | Sony Corp | 浮上型磁気ヘッド装置 |
JPH05298850A (ja) | 1992-04-22 | 1993-11-12 | Hitachi Ltd | 磁気記録装置およびそのスライダ |
JPH07102113B2 (ja) | 1992-11-18 | 1995-11-08 | 日成興産株式会社 | 痩身用食品 |
JPH0813257B2 (ja) * | 1992-11-25 | 1996-02-14 | 日成興産株式会社 | 痩身用食品 |
JP3230884B2 (ja) * | 1993-03-18 | 2001-11-19 | 日清製油株式会社 | 冷凍解凍耐性のあるクリーム状組成物及びその製造方法 |
JP2605208B2 (ja) | 1993-04-15 | 1997-04-30 | 逸郎 松島 | 痩身用食品 |
JP2510943B2 (ja) | 1993-06-07 | 1996-06-26 | 株式会社ドクターマインツ | 痩身用食品 |
DE4331565A1 (de) | 1993-09-16 | 1995-03-23 | Consortium Elektrochem Ind | Verfahren zur Reduktion des Gehalts an Triglyceriden im Eigelb und in eigelbhaltigen Produkten |
JPH07115935A (ja) * | 1993-10-22 | 1995-05-09 | Hairu:Kk | 痩身用食品 |
JPH07115934A (ja) | 1993-10-22 | 1995-05-09 | Hairu:Kk | 痩身用食品 |
US5894029A (en) * | 1994-03-21 | 1999-04-13 | Purebred Pet Products, Inc. | Method of making pet snack food |
JPH09501186A (ja) * | 1994-11-12 | 1997-02-04 | 株式会社エルジ化学 | コレステリルエステル運搬蛋白質阻害ペプチドおよびこれを含む動脈硬化症のための予防および治療剤 |
BR9607725A (pt) * | 1995-02-22 | 1999-11-30 | Chris Ritter | Processo para reduzir esteróis e ácidos graxos livres de gordura animal |
JP3375780B2 (ja) | 1995-03-29 | 2003-02-10 | 三井化学株式会社 | 重包装袋用ポリエチレン樹脂組成物およびその組成物からなる重包装袋用ポリエチレン樹脂フィルム |
US5738898A (en) | 1995-03-31 | 1998-04-14 | Board Of Trustees Operating Michigan State University | Process for reducing sterols in eggs |
US5560950A (en) * | 1995-05-31 | 1996-10-01 | Campbell Soup Company | Free fatty acid removal from used frying fat |
US5532009A (en) * | 1995-06-07 | 1996-07-02 | The Procter & Gamble Company | Fat substitutes containing water soluble beta-carotene |
JP2934658B2 (ja) * | 1995-12-25 | 1999-08-16 | 美穂 田中 | クロレラエキス粉末の製造法 |
IL117773A (en) * | 1996-04-02 | 2000-10-31 | Pharmos Ltd | Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability |
US5965449A (en) * | 1996-07-03 | 1999-10-12 | Forbes Medi-Tech, Inc. | Method of assessing risk for cardiovascular disease and other disorders and phytosterol-based compositions useful in preventing and treating cardiovascular disease and other disorders |
JP2000116337A (ja) | 1998-10-09 | 2000-04-25 | Nippon Shokuhin Kako Co Ltd | ペットフード |
US6129945A (en) * | 1998-12-10 | 2000-10-10 | Michael E. George | Methods to reduce free fatty acids and cholesterol in anhydrous animal fat |
JP2002306119A (ja) * | 2001-04-17 | 2002-10-22 | Toyo Olive Co Ltd | 健康維持機能に優れたオリーブマヨネーズの製造法 |
US20030190402A1 (en) | 2002-04-04 | 2003-10-09 | Mcbride Christine | Reduced fat foodstuff with improved flavor |
US20030232068A1 (en) * | 2002-06-14 | 2003-12-18 | Lewandowski Daniel J. | Food product having increased bile acid binding capacity |
IL164332A0 (en) * | 2002-08-19 | 2005-12-18 | Art Jen Complexus Inc | Compositions comprising dietary fat complexer and methods for their use |
US20040116382A1 (en) * | 2002-12-13 | 2004-06-17 | Plank David W. | Food products containing cyclodextrins having beneficial hypocholesterolemic effects and method of making and communicating the benefit of such products |
-
2003
- 2003-07-29 IL IL16433203A patent/IL164332A0/xx unknown
- 2003-07-29 DK DK09011371.3T patent/DK2138190T3/da active
- 2003-07-29 PL PL405077A patent/PL220776B1/pl unknown
- 2003-07-29 WO PCT/US2003/023291 patent/WO2004016101A2/en active Application Filing
- 2003-07-29 PL PL405075A patent/PL220780B1/pl unknown
- 2003-07-29 EP EP12196392.0A patent/EP2623120B1/en not_active Expired - Lifetime
- 2003-07-29 NZ NZ535665A patent/NZ535665A/en not_active IP Right Cessation
- 2003-07-29 CA CA2677430A patent/CA2677430C/en not_active Expired - Fee Related
- 2003-07-29 DK DK03788275.0T patent/DK1478401T3/da active
- 2003-07-29 JP JP2004529193A patent/JP4418751B2/ja not_active Expired - Fee Related
- 2003-07-29 CN CNB038143364A patent/CN100542609C/zh not_active Expired - Fee Related
- 2003-07-29 EP EP03788275A patent/EP1478401B1/en not_active Expired - Lifetime
- 2003-07-29 SI SI200332347T patent/SI2138190T1/sl unknown
- 2003-07-29 MX MXPA04012880A patent/MXPA04012880A/es active IP Right Grant
- 2003-07-29 EP EP12196390.4A patent/EP2641615A3/en not_active Withdrawn
- 2003-07-29 ES ES09011371.3T patent/ES2457017T3/es not_active Expired - Lifetime
- 2003-07-29 PL PL396944A patent/PL220645B1/pl unknown
- 2003-07-29 BR BRPI0309572A patent/BRPI0309572B1/pt not_active IP Right Cessation
- 2003-07-29 US US10/628,475 patent/US6890549B2/en not_active Expired - Lifetime
- 2003-07-29 PL PL405074A patent/PL220643B1/pl unknown
- 2003-07-29 PT PT90113713T patent/PT2138190E/pt unknown
- 2003-07-29 AU AU2003259235A patent/AU2003259235B2/en not_active Ceased
- 2003-07-29 DE DE60329168T patent/DE60329168D1/de not_active Expired - Lifetime
- 2003-07-29 PL PL375374A patent/PL213863B1/pl unknown
- 2003-07-29 PL PL405076A patent/PL220779B1/pl unknown
- 2003-07-29 CA CA002480668A patent/CA2480668C/en not_active Expired - Fee Related
- 2003-07-29 EP EP09011371.3A patent/EP2138190B1/en not_active Expired - Lifetime
- 2003-07-29 AT AT03788275T patent/ATE442165T1/de active
-
2004
- 2004-08-23 US US10/923,000 patent/US8101201B2/en not_active Expired - Fee Related
- 2004-09-28 ZA ZA2004/07806A patent/ZA200407806B/en unknown
- 2004-09-28 IL IL164332A patent/IL164332A/en active IP Right Grant
- 2004-09-28 MA MA27879A patent/MA27959A1/fr unknown
- 2004-10-21 NO NO20044516A patent/NO334081B1/no not_active IP Right Cessation
-
2005
- 2005-04-06 HK HK05102859.1A patent/HK1072184A1/xx not_active IP Right Cessation
-
2009
- 2009-09-30 JP JP2009225737A patent/JP5448683B2/ja not_active Expired - Fee Related
-
2010
- 2010-06-04 HK HK10105541.1A patent/HK1140407A1/xx not_active IP Right Cessation
-
2011
- 2011-12-30 US US13/340,879 patent/US8586076B2/en not_active Expired - Fee Related
-
2013
- 2013-04-22 NO NO20130555A patent/NO339166B1/no not_active IP Right Cessation
- 2013-06-07 JP JP2013120786A patent/JP5865296B2/ja not_active Expired - Fee Related
- 2013-08-30 US US14/015,455 patent/US9326539B2/en not_active Expired - Fee Related
-
2014
- 2014-04-09 CY CY20141100266T patent/CY1115026T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL405076A1 (pl) | Zastosowanie alpha-cyklodrkstryny do wytwarzania leku do obnizenia poziomów leptyny, poziomów insuliny lub opornosci na insuline | |
TW200718418A (en) | Cannabinoid active pharmaceutical ingredient for improved dosage forms | |
BRPI0519803A2 (pt) | métodos para purificar trans-(-)-delta9-tetraidrocanabinol e trans-(+)-delta9-tetraidrocanabinol | |
BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
MXPA04004837A (es) | Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1. | |
MXPA04004842A (es) | Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1. | |
TW200633696A (en) | Sesamin/episesamin compositions | |
WO2007028058A3 (en) | Adjustable stiffness catheter | |
MY137053A (en) | Pyrimidine derivatives and their use as cb2 modulators | |
WO2006044362A3 (en) | N-sulfonylpiperidine cannabinoid receptor 1 antagonists | |
CY1114979T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν ορνιθινη και φαινυλοξικο ή φαινυλοβουτυρικο για αντιμετωπιση ηπατικης εγκεφαλοπαθειας | |
GB0222495D0 (en) | Compounds | |
AU2804400A (en) | Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists | |
MXPA05002930A (es) | Composiciones para la inhibicion de la proteina cinasa c alfa para el tratamiento de diabetes mellitus y enfermedades cardiovasculares. | |
TW200503773A (en) | Composition for external use | |
EP1281398A4 (en) | DERMAL COMPOSITIONS HAVING COENZYME Q AS ACTIVE INGREDIENT | |
UA92498C2 (ru) | Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм | |
WO2008058358A3 (en) | Descriptive report of the patent of invention of the medicament 'rosuvastatin + metformin' in combined form for cardiovascular diseases. | |
MY139498A (en) | Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines | |
RS44204A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
SE0102147D0 (sv) | New methods | |
BR0308229A (pt) | Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio | |
EP1819724A4 (en) | BETA 2-GLYCOPROTEIN I COMPOSITIONS FOR THE PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES | |
BR9904890A (pt) | "compostos de heteroetinileno, composição farmacêutica, composição cosmética e utilização de uma composição cosmética" | |
BR0314451A (pt) | Composição lìquida de limpeza pessoal |